Vivo Ventures aims for Asia investment with $275M fund
Vivo Ventures plans its first in Asian life-science investments now that it has closed a new fund, VentureWire is reporting (subscription required). The Palo Alto, Calif., outfit, formerly known as BioAsia Investments due to its former association with Asian investors, just closed a $275 million healthcare fund, its sixth.
From the VentureWire story:
Vivo expects to invest this fund in 14 to 18 companies, with a particular emphasis on those with drugs or medical devices in clinical… Continue Reading